préXclude
The Rapid Preeclampsia Test
Introducing préXclude - our ground-breaking rapid preeclampsia test designed for the eFlow system - the fastest and most precise method for detecting preeclampsia in pregnant women. Our test requires only a simple fingerstick blood sample and delivers results in minutes, making it highly convenient for use in hospitals, clinics, and even at home. Our test can assist in assessing the likelihood of pregnant women developing severe preeclampsia in the coming weeks. This enables prompt medical intervention improving outcomes for mother and baby.
Act proactively – préXclude offers early preeclampsia prognosis during prenatal checkups.
préXclude
The Rapid Preeclampsia Test
A powerful assay:
Our test utilizes well-established biomarkers (sFlt-1, PlGF) that are highly sensitive and specific, delivering a proven accuracy rate of over 95% in centralized lab assays [1-4]. Through our proprietary technology, we have achieved a significant breakthrough by enabling the measurement of these biomarkers with an affordable near-patient test, marking a milestone in the field.
A compact instrument:
MOMM Diagnostics patented diagnostics platform eFlow is designed for near-patient settings, including clinics and at-home testing. It offers the sensitivity of lab-based assays at the point-of-care. eFlow’s innovative features include a compact and low-cost reader that delivers results rapidly with minimal hands-on time and training. These features make it user-friendly and accessible to healthcare providers and patients alike.
Please note that préXclude and eFlow are currently in the development phase and are not yet available for commercial use. We are working diligently to bring this innovative technology to market as soon as possible and look forward to making it accessible to healthcare providers and patients worldwide.
1 Andersen et al. J Am Soc Hypertens, 2015
2 van Helden et al. Clin Biochem, 2015